About Us

Cannim’s story is one of purpose driven collaboration to help those suffering needlessly when medicinal cannabis can help; a passion to help Jamaica and to keep Australia at the forefront of medical advances; and the aspiration to be the Australasian leader of the global movement in the fastest growing industry worldwide.

Cannim’s genesis was the four Worton brothers in Jamaica and Australia who recognised the benefits of medicinal cannabis from personal memories that it provided pain relief in cancer (and also helped treat asthma attacks and anxiety with “ganja tea”!).

After research and meetings with people involved in cannabis cultivation, processing, hardware, cannabis testing labs, budding cannabis venture capitalists, doctors and universities in geographies ranging from Jamaica to California, Oregon and Massachusetts as well as Australia, a plan to enter the market evolved.

The plan was based on 3 issues identified:

• quality standards and product information were not widespread
• cultivation was traditionally an “art” rather than a consistent approach
• production was fragmented with unpredictable supply

Based on prior experience with raising capital and listing businesses in the USA and Australia, the bold plan initiated was to create a business with a scale that could significantly impact the global industry.

Jamaica Red Moon was incorporated in Jamaica in January 2017 with Cannim Group incorporated in Australia afterwards.

One of the first decisions was to acquire a farm of 500 acres in Jamaica.

However, with the brothers recognising their limitations, the very first decision was to identify and recruit an expert team.

This is Cannim’s main asset: a committed, diverse team with a demonstrable track record of success in their fields. The team includes world renown thought leaders and pioneers from Israel effectively transplanting Israel’s global market leadership in medicinal cannabis to Cannim’s Jamaican operations. Other expertise ranges from managing farms over 1,000s of acres, “big-pharma” and drug development; legal and M&A, regulatory compliance, logistics and security; through to capital markets and entrepreneurial acumen.

Cannabis culture runs deep in the soul of Jamaica. Not just in the popular image of Bob Marley and reggae music or even as a spiritual sacrament by Rastafarians and their association with “ganja”. Cannabis has been an integral part of traditional Jamaican remedies with an infusion of cannabis in white over-proof rum a staple component of every grandmothers’ medicine cabinet.

Less well known is that the first approved pharmaceutical drug developed from cannabis was in Jamaica in 1983 called Canasol for the treatment of Glaucoma, with Asthmasol launched for the treatment of Asthma in 1990.

Importantly, widespread use of cannabis in Jamaica means it is a beacon to researchers who want to study its effects.

Australia’s cannabis legislation was slower to develop than in Jamaica so Cannim’s priority was on securing licenses, initiating cultivation and generating revenue from Jamaica.

Cannim has now acquired an Australian farm and has applied for licenses to replicate its Jamaican operations. and to leverage the global talent and capital it has attracted. Underpinned by research, Australian operations will focus on the emerging Australian and Asian markets.

Bold visions cannot be achieved alone and Cannim attracted talent and formed alliances to cooperate internationally on systems, strains and know-how developed over combined decades of anecdotal and regulated use of medicinal cannabis.

From our strategic beach-heads in Israel, Jamaica, Australia, the UK and Europe, we are extending our relationships to the China, Asia, Africa and the Americas.

With significant offtake agreements already established, our common purpose of delivering medicinal cannabis as part of cannabis’ movement from the shadow into the light© is being achieved.